Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Expert Opin Pharmacother. 2010 Dec;11(17):2891–2906. doi: 10.1517/14656566.2010.515979

Table 1.

Cotswold Modification of the Ann Arbor Staging for HL

Stage Description
I Involvement of a single lymph node region or lymphoid structure
II Involvement of ≥ two lymph node regions on the same side of the diaphragm
III Involvement of lymph node regions on both sides of the diaphragm
III1 With or without involvement of splenic, hilar, celiac, or portal nodes
III2 With involvement of para-aortic, iliac, and mesenteric nodes
IV Diffuse or disseminated involvement of one or more extranodal organs or tissues,
with or without associated lymph node involvement
A No symptoms
B Fever (temperature, >38°C [100.4°F]), drenching night sweats, unexplained loss of
>10% of body weight within the preceding 6 months
X Bulky disease (a widening of the mediastinum by more than one-third due to
presence of a nodal mass with a maximal dimension greater than 10 cm)
E Involvement of a single extranodal site that is contiguous or proximal to the known
nodal site
CS Clinical stage
PS Pathologic stage